8-K: Cibus Reports Full Year 2023 Results, Highlights Commercial Progress in Gene Editing

Cibus, Inc. announced its full year 2023 financial results and provided a business update, highlighting commercial advancements in its gene editing technology and collaborations with major seed companies.

Summary

• Cibus, Inc. reported its financial results for the year ended December 31, 2023, showcasing significant progress in its commercial strategy.
• The company successfully transferred gene-edited elite germplasm to customers for commercialization across three developed productivity traits: Pod Shatter Reduction (PSR) in Canola and Herbicide Tolerance (HT1 and HT3) in Rice.
• Cibus signed collaboration agreements with major seed companies like Bayer, Loveland Products, Nuseed, and Interoc for trait development.
• They achieved positive greenhouse results for two modes of action for Sclerotinia (White Mold) Resistance in Canola and successful 2023 field trial results for all developed productivity traits.
• A new high-throughput gene editing production facility was opened to support the scaling of Cibus' crop and trait pipeline.
• The EU Parliament's positive vote on new genomic techniques (NGTs) is expected to benefit Cibus' gene editing technology.
• Cibus achieved a major breakthrough by successfully regenerating Wheat plants from single cells.
• The company raised $20.3 million through a registered direct offering in the fourth quarter of 2023.
• Cibus reported a net loss of $277.2 million for the quarter ended December 31, 2023, primarily due to a $249.4 million non-cash goodwill and intangible assets impairment.
• Cash and cash equivalents were $32.7 million as of December 31, 2023, expected to fund operations into early third quarter of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are significant technological and commercial achievements, the substantial net loss and the need for additional funding temper the positive aspects. The sentiment is neutral to slightly negative due to the financial challenges.

Positives

• Cibus has made significant commercial progress with its three developed traits, including transfers to customers.
• The company has established strong partnerships with major seed companies.
• Cibus' gene editing technology is gaining regulatory support in the EU.
• The company has achieved significant technological breakthroughs, such as the regeneration of Wheat plants from single cells.
• Cibus has opened a new high-throughput gene editing facility to support its growing pipeline.
• The company successfully raised $20.3 million in the fourth quarter of 2023.

Negatives

• Cibus reported a substantial net loss of $277.2 million for the quarter ended December 31, 2023.
• The net loss was primarily driven by a $249.4 million non-cash goodwill and intangible assets impairment.
• The company's cash and cash equivalents of $32.7 million are expected to fund operations only into early third quarter of 2024.
• Research and development expenses increased significantly to $14.2 million for the quarter ended December 31, 2023, compared to $2.3 million in the year-ago period.
• Selling, general, and administrative expenses also increased to $6.8 million for the quarter ended December 31, 2023, compared to $1.0 million in the year-ago period.

Risks

• Cibus needs additional near-term funding to finance its activities and faces challenges in obtaining additional capital.
• The company faces competition and challenges to its intellectual property protection.
• There are risks associated with the commercialization of Cibus' traits, including farmer adoption and market acceptance.
• Regulatory developments could impose burdens on gene-editing processes or products.
• The company is dependent on distributions from Cibus Global, LLC to pay taxes and cover its corporate and overhead expenses.
• Cibus faces risks associated with the possible failure to realize certain anticipated benefits of the Merger Transactions.

Future Outlook

Cibus expects to achieve several development and commercial milestones in 2024, including expanding its customer base, advancing its Sclerotinia resistance and HT2 traits, and operationalizing its Soybean platform. They also plan to complete editing discovery efforts for alternative oils for the CPG industry.

Management Comments

• 2023 was a pivotal year for Cibus, both in terms of our evolution as a public company following the merger with Calyxt and the implementation of our commercial strategy as we transformed from our research and development origins, stated Rory Riggs, Co-Founder, Chairman, and CEO of Cibus.
• The centerpiece of our commercialization goals are the commercial advancement of each of our three developed traits Pod Shatter Reduction in Canola, and our two herbicide tolerance traits in Rice, HT1 and HT3.
• We truly believe Cibus is at the forefront of agriculture's analog to digital moment and we are excited about our continued commercial progress in the months and quarters to come.

Industry Context

The positive vote in the EU Parliament regarding new genomic techniques is a significant development for the gene editing industry, potentially opening up new markets for companies like Cibus. This move aligns with a broader trend towards adopting advanced technologies in agriculture to improve productivity and sustainability.

Comparison to Industry Standards

• Cibus' focus on high-throughput gene editing aligns with the industry's move towards faster and more efficient trait development, similar to companies like Corteva Agriscience and Bayer Crop Science who are also investing in gene editing technologies.
• The successful regeneration of wheat plants from single cells is a significant achievement, as wheat is a notoriously difficult crop to edit, and this puts Cibus ahead of many competitors in this area.
• The company's approach of licensing traits to seed companies rather than becoming a seed producer is similar to other biotech companies like Pairwise, which focuses on technology development and licensing.
• The reported net loss and cash burn are not uncommon for early-stage biotech companies, but the magnitude of the impairment charge is significant and warrants close monitoring compared to peers.

Related Party Transactions

• Royalty liability interest expense related parties was $8.1 million for the quarter ended December 31, 2023, a non-cash expense.

Stakeholder Impact

• Shareholders are impacted by the significant net loss and the potential need for additional capital raising.
• Employees are impacted by the increase in headcount and stock-based compensation.
• Customers (seed companies) are impacted by the successful transfer of gene-edited germplasm and the potential for new trait development.
• Suppliers are impacted by the increased lab supply and facility expenses.
• Creditors are impacted by the company's financial performance and cash position.

Next Steps

• Cibus expects 8 of 10 PSR customers in Canola to have their elite germplasm edited with Cibus' trait either transferred to the customer or ready to be transferred by year end 2024.
• The company plans to expand its customer base with existing developed productivity traits.
• Cibus expects greenhouse results for a third mode of action for Sclerotinia resistance.
• They also expect greenhouse results for HT2.
• The Soybean single-cell regeneration platform will be operational and have initial editing completed.
• Cibus expects to demonstrate initial edits toward developing productivity traits for Wheat.
• The company plans to complete editing discovery efforts for alternative oils for the CPG industry.

Key Dates

Keywords

gene editing, agricultural biotechnology, plant traits, seed companies, RTDS, crop development, commercialization, pod shatter reduction, herbicide tolerance, sclerotinia resistance, wheat regeneration, financial results